Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.34 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.37 +0.03 (1.28%) 4:48 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Brokerage Reports
Esperion Therapeutics, Inc. [ESPR]
Reports for Purchase
Showing records 41 - 60 ( 160 total )
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
ESC Highlights CLEAR Patient Benefit With Updated Outcomes Data; Label Expansion Expected 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
2Q23 Results; BDA's Potential Global Label Expansions in 1H24 Set Stage for Continued Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
NILEMDO and NUSTENDI File Expanded Indication Applications For CVR Reduction in Europe; Regulatory Reviews Ongoing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
ADA Highlights BDA's Efficacy to Reduced MACE in Primary Prevention Population
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA?s Label Change For CVR Reduction Submitted; Potential U.S. Approval in 1H24; E.U. Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Results; Growing Interest For BDA; Potential Global Label Expansions in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA Regulatory Filings to FDA and EMA in 1H23; Milestone Payments Under Debate
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Paradigm Shift Likely; Expert Panel Recommends BDA Ahead of Other Non-Statin LDL-C Lowering Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Crystal CLEAR Outcomes Data; Label Expansion Expected in 1H24; Reiterate Top Pick
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J